Hubei Biocause Heilen Pharmaceutical Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Hubei Biocause Heilen Pharmaceutical.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 18.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Shareholders Have More To Worry About Than Lackluster Earnings
Nov 04
Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211) After Shares Rise 43%
Oct 30Earnings Not Telling The Story For Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SZSE:301211)
Aug 07Hubei Biocause Heilen Pharmaceutical (SZSE:301211) Will Pay A Larger Dividend Than Last Year At CN¥0.48
May 22Hubei Biocause Heilen Pharmaceutical's (SZSE:301211) Promising Earnings May Rest On Soft Foundations
Apr 29In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hubei Biocause Heilen Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 455 | 106 | -104 | 103 | N/A |
| 6/30/2024 | 499 | 132 | -95 | 122 | N/A |
| 3/31/2024 | 608 | 174 | -61 | 167 | N/A |
| 12/31/2023 | 663 | 176 | -49 | 137 | N/A |
| 9/30/2023 | 712 | 192 | 53 | 210 | N/A |
| 6/30/2023 | 680 | 184 | 70 | 206 | N/A |
| 3/31/2023 | 580 | 138 | 85 | 176 | N/A |
| 1/1/2023 | 515 | 126 | 175 | 251 | N/A |
| 9/30/2022 | 468 | 101 | 147 | 172 | N/A |
| 6/30/2022 | 504 | 108 | 145 | 157 | N/A |
| 3/31/2022 | 548 | 113 | 139 | 156 | N/A |
| 1/1/2022 | 541 | 122 | 103 | 124 | N/A |
| 9/30/2021 | 589 | 138 | 101 | 116 | N/A |
| 6/30/2021 | 576 | 144 | 64 | 82 | N/A |
| 3/31/2021 | 567 | 159 | 85 | 99 | N/A |
| 12/31/2020 | 593 | 168 | 108 | 122 | N/A |
| 12/31/2019 | 660 | 100 | 340 | 372 | N/A |
| 12/31/2018 | 517 | 48 | 51 | 76 | N/A |
| 12/31/2017 | 366 | 10 | N/A | -65 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 301211's forecast earnings growth is above the savings rate (2.8%).
Earnings vs Market: Insufficient data to determine if 301211's earnings are forecast to grow faster than the CN market
High Growth Earnings: Insufficient data to determine if 301211's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 301211's revenue is forecast to grow faster than the CN market.
High Growth Revenue: Insufficient data to determine if 301211's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 301211's Return on Equity is forecast to be high in 3 years time